Dozens of new obesity drugs are coming: these are the ones to watch Semaglutide, Tirzepatide, Retatrutide and Cagrilintide are often lumped together, but they are not doing the same thing. : r Wegovy PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed., A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug